These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 20368559)

  • 1. Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104.
    Partridge AH; Archer L; Kornblith AB; Gralow J; Grenier D; Perez E; Wolff AC; Wang X; Kastrissios H; Berry D; Hudis C; Winer E; Muss H
    J Clin Oncol; 2010 May; 28(14):2418-22. PubMed ID: 20368559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of life of older patients with early-stage breast cancer receiving adjuvant chemotherapy: a companion study to cancer and leukemia group B 49907.
    Kornblith AB; Lan L; Archer L; Partridge A; Kimmick G; Hudis C; Winer E; Casey R; Bennett S; Cohen HJ; Muss HB
    J Clin Oncol; 2011 Mar; 29(8):1022-8. PubMed ID: 21300923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant chemotherapy in older women with early-stage breast cancer.
    Muss HB; Berry DA; Cirrincione CT; Theodoulou M; Mauer AM; Kornblith AB; Partridge AH; Dressler LG; Cohen HJ; Becker HP; Kartcheske PA; Wheeler JD; Perez EA; Wolff AC; Gralow JR; Burstein HJ; Mahmood AA; Magrinat G; Parker BA; Hart RD; Grenier D; Norton L; Hudis CA; Winer EP;
    N Engl J Med; 2009 May; 360(20):2055-65. PubMed ID: 19439741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907).
    Ruddy KJ; Pitcher BN; Archer LE; Cohen HJ; Winer EP; Hudis CA; Muss HB; Partridge AH
    Ann Oncol; 2012 Dec; 23(12):3075-3081. PubMed ID: 22767584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer.
    Babacan T; Efe O; Hasirci AS; Demirci F; Buyukhatipoglu H; Balakan O; Sarici F; Kertmen N; Esin E; Akin S; Ates O; Aksoy S; Sever AR; Altundag K
    Tumori; 2015; 101(4):418-23. PubMed ID: 25953439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
    Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Paija O; Helle L; Villman K; Nyandoto P; Nilsson G; Pajunen M; Asola R; Poikonen P; Leinonen M; Kataja V; Bono P; Lindman H
    J Clin Oncol; 2012 Jan; 30(1):11-8. PubMed ID: 22105826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Capecitabine in elderly patients with metastatic breast cancer.
    De Sanctis R; Quadrini S; Longo F; Lapadula V; Restuccia R; Del Signore E; De Filippis L; Stumbo L; Gori B; Bianco V; Speranza I; Basile ML; Di Seri M
    Tumori; 2012; 98(3):303-7. PubMed ID: 22825504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comorbidity, chemotherapy toxicity, and outcomes among older women receiving adjuvant chemotherapy for breast cancer on a clinical trial: CALGB 49907 and CALGB 361004 (alliance).
    Klepin HD; Pitcher BN; Ballman KV; Kornblith AB; Hurria A; Winer EP; Hudis C; Cohen HJ; Muss HB; Kimmick GG
    J Oncol Pract; 2014 Sep; 10(5):e285-92. PubMed ID: 25074878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer.
    Rudek MA; Connolly RM; Hoskins JM; Garrett-Mayer E; Jeter SC; Armstrong DK; Fetting JH; Stearns V; Wright LA; Zhao M; Watkins SP; McLeod HL; Davidson NE; Wolff AC
    Breast Cancer Res Treat; 2013 May; 139(1):135-43. PubMed ID: 23588952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
    Rossi D; Alessandroni P; Catalano V; Giordani P; Fedeli SL; Fedeli A; Baldelli AM; Casadei V; Ceccolini M; Catalano G
    Clin Breast Cancer; 2007 Dec; 7(11):857-60. PubMed ID: 18269775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicity profile and efficacy of oral capecitabine as adjuvant chemotherapy for Chinese patients with Stage III colon cancer.
    Law CC; Fu YT; Chau KK; Choy TS; So PF; Wong KH
    Dis Colon Rectum; 2007 Dec; 50(12):2180-7. PubMed ID: 17963003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Capecitabine non-adherence: exploration of magnitude, nature and contributing factors.
    Bhattacharya D; Easthall C; Willoughby KA; Small M; Watson S
    J Oncol Pharm Pract; 2012 Sep; 18(3):333-42. PubMed ID: 22298660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial.
    Muss HB; Polley MC; Berry DA; Liu H; Cirrincione CT; Theodoulou M; Mauer AM; Kornblith AB; Partridge AH; Dressler LG; Cohen HJ; Kartcheske PA; Perez EA; Wolff AC; Gralow JR; Burstein HJ; Mahmood AA; Sutton LM; Magrinat G; Parker BA; Hart RD; Grenier D; Hurria A; Jatoi A; Norton L; Hudis CA; Winer EP; Carey L
    J Clin Oncol; 2019 Sep; 37(26):2338-2348. PubMed ID: 31339827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial.
    von Minckwitz G; Kümmel S; Vogel P; Hanusch C; Eidtmann H; Hilfrich J; Gerber B; Huober J; Costa SD; Jackisch C; Loibl S; Mehta K; Kaufmann M;
    J Natl Cancer Inst; 2008 Apr; 100(8):542-51. PubMed ID: 18398097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of preoperative capecitabine in women with operable hormone receptor positive breast cancer.
    Tolaney SM; Jeong J; Guo H; Brock J; Morganstern D; Come SE; Golshan M; Bellon J; Winer EP; Krop IE
    Cancer Med; 2014 Apr; 3(2):293-9. PubMed ID: 24464780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Oral capecitabine as postoperative adjuvant chemotherapy in stage III colon cancer patients].
    Yamaguchi T; Fukuda M; Yasui H; Okazaki S; Kubo K; Tanaka M; Une Y; Setoguchi Y; Hanada K; Moriyama S; Tani M; Murakami T; Okuchi Y; Ogiso S; Hata H; Sakata S; Otani T; Yamato T; Ikai I
    Gan To Kagaku Ryoho; 2012 Mar; 39(3):389-93. PubMed ID: 22421765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Adjuvant chemotherapy in older women with breast cancer. CALGB Study (The Cancer and Leukemia Group B Study)].
    Mallmann P; Nitschmann S
    Internist (Berl); 2010 Jul; 51(7):923-4. PubMed ID: 20544172
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women.
    Bajetta E; Procopio G; Celio L; Gattinoni L; Della Torre S; Mariani L; Catena L; Ricotta R; Longarini R; Zilembo N; Buzzoni R
    J Clin Oncol; 2005 Apr; 23(10):2155-61. PubMed ID: 15710946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.
    Gajria D; Gonzalez J; Feigin K; Patil S; Chen C; Theodoulou M; Drullinsky P; D'Andrea G; Lake D; Norton L; Hudis CA; Traina TA
    Breast Cancer Res Treat; 2012 Jan; 131(1):111-6. PubMed ID: 21898114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of 4-weekly capecitabine monotherapy in advanced/metastatic breast cancer.
    Kusama M; Nomizu T; Aogi K; Yoshimoto M; Horikoshi N; Tabei T; Noguchi S; Miura S; Yoshimura N; Kimura M; Toyama K; Shin E
    Breast Cancer; 2010 Oct; 17(4):233-40. PubMed ID: 19633909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.